Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)

NCT00248183 is registered in ClinicalTrials.gov with Epix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00248183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00248183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)
Lead sponsor
Epix Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2005
Completion date
June 30, 2006
Enrollment
310
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety disorders